Tripelennamine Hydrochloride

Gibberellic acid (GA₃) is inhibitory to floral development of in vitro cannabis plants and inhibiting GA₃ biosynthesis promotes floral development. As such, paclobutrazol (PBZ), a potent GA₃ biosynthesis inhibitor may be useful for increasing floral biomass and expediting development, but due to health concerns, its use is prohibited in cannabis production. The present study was conducted to compare the use of PBZ with tannic acid (TA), a natural compound with potential GA₃ inhibiting characteristics. Results confirmed that PBZ significantly affected the number of flowers, percentage of flowering plantlet, and flower appearance time. Treatment using PBZ at a concentration of 10 μM resulted in the greatest number of flowers (7.95) compared to other treatments. Moreover, this compound at concentrations of 5 and 10 μM yielded the highest percentage of flowering plantlets, at 75 % and 70 %, respectively. Flowers also appeared 7-15 days sooner than other treatments. Additionally, the energy transfer efficiency in the photosynthetic system and chlorophyll concentration in plants treated with PBZ were considerably higher than those under other treatments. Under the PBZ treatment, the length of internode was significantly reduced. In contrast, TA generally had the opposite effect of PBZ, suggesting that it does not act as a GA₃ inhibitor in this context. Furthermore, positive effects of TA at a concentration of 10 μM were observed on total leaf area (840.08 mm²) and stem length (40.09 mm). The highest number of leaves (12.5) was found in the presence of TA at a concentration of 100 μM. TA at its highest concentration (1000 μM) had an inverse effect on cannabis growth and flowering but was likely due to toxicity rather than any inhibitory effects. Consequently, the obtained results confirm the importance of growth regulators and natural compounds on plant growth and can broaden our understanding for future research and achievement of objectives.

Phenylbutazone (PBZ) is a widely used nonsteroidal anti-inflammatory drug for horses. However, because of its gastrointestinal side effects, its administration requires careful attention in veterinary practice. Malondialdehyde (MDA) is a serum biomarker associated with increased damage to the equine gastrointestinal system. This study investigated the hematological effects and alterations in the gastrointestinal tract and assessed serum MDA concentrations following repeated oral PBZ administration at clinical doses. Fourteen horses were randomly divided into control and treatment groups. All horses in the treatment group were administered 4.4 milligrams per kilogram of body weight of PBZ syrup orally twice a day for 7 days, whereas the control group received syrup as a placebo. The development of gastrointestinal side effects was investigated using gastroscopy, abdominal ultrasound, and fecal pH; serum MDA concentrations were assessed using a commercially available enzyme-linked immunosorbent assay kit. Data were compared between PBZ-treated and control horses before and after the treatment period. The treatment group exhibited decreased albumin and total protein concentrations. Moreover, this group exhibited a higher thickness of the right dorsal colon wall (p = 0.03) and had higher scores for squamous gastric ulcers (p = 0.01). Fecal pH was lower in the treatment group than in the control group after PBZ administration (p < 0.01). Although MDA concentrations were higher in the treatment group after PBZ administration, they did not differ significantly from those of the control group. This study highlighted the changes in hematological and gastrointestinal lesions resulting from PBZ administration in horses at clinical doses, even without clinical signs. However, MDA may not be an optimal biomarker for the early detection of gastrointestinal damage due to PBZ treatment in horses.